Since the emergence of SARS-CoV-2, continuous mutations and evolutions have led to increased transmissibility and immune evasion capabilities, resulting in the emergence of several variants. Neutralizing antibodies against SARS-CoV-2 can prevent virus entry into the human body by inhibiting the interaction between the spike protein on the virus surface and the host cell receptor angiotensin-converting enzyme 2 (ACE2). These neutralizing antibodies can be produced after vaccination with COVID-19 vaccines or infection with SARS-CoV-2. We have developed a high-throughput and high-sensitivity broad-spectrum neutralizing antibody detection technology (SARS-CoV-2 bNAb assay) for SARS-CoV-2 variants. This technology can be used on commonly available flow cytometers and is capable of systematically detecting neutralizing antibodies against a wide range of SARS-CoV-2 variants, including D614G, Alpha, Beta, Gamma, Delta, Kappa, Omicron BA.1-BA.5, Omicron XBB, BQ1.1, BF.7, EG.5, and others.